Based on its recent analysis of the water treatment market, Frost & Sullivan awarded BioLargo Water, Inc., a wholly-owned subsidiary of BioLargo, Inc. (OTCQB:BLGO), with the 2015 North American Frost & Sullivan Award for New Product Innovation.
The AOS filter, the lowest cost contender, is a system that facilitates continuous and scalable treatment with maximum efficiency, using GRAS components to destroy contaminants. Complete with multiple filter systems, the AOS filter quickly destroys contaminants, and is able to extend the life of the filtration systems. Improving upon traditional activated carbon filters, the AOS Filter performs a disinfection task similar to UV or ozone at much lower price points. It demonstrates impressive levels of disinfection, removing infectious biological pathogens such as Salmonella, Listeria, and E. coli in water. It is also extremely effective in removing soluble organics such as napthenic acids, dioxane, sulfur compounds, ammonia, benzene, fungi, and spores.
"The AOS Filter generates high levels of oxidation potential across surfaces within the device by converting a typical carbon matrix filter into an electrochemical reactor," said Frost & Sullivan Senior Industry Analyst, Seth Cutler. "This amplification of the oxidation potential of iodine, a key natural disinfectant, creates different and powerful forms of iodine, greatly enhancing its efficacy."
Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, enhances customer acquisition and overall market penetration potential.
BioLargo’s impressive and steady progress garnered major headlines in 2015. Some operational highlights include:
- Grants and financial awards to advance the BioLargo AOS Filter to commercialization that exceed $1,000,000 and counting.
- BioLargo’s science team continues to gain peer acceptance, as evidenced by their recent attendance at the EUREKA ACQUEAU Conference in Paris France.
- The first pilot is being organized in the poultry processing industry, working with a major poultry producer in Canada.
- The company has completed a $1,000,000 capital raise and restructured their short-term debt into long term and mandatorily convertible debt.
- Expansion of staff, including Dr. Parastoo Pourrezaei, E.I.T., a professional researcher and engineer with substantial experience in the oil sands industry, and Charles Dargan, the company’s CFO, agreed to extend his tenure.
- Three distinct iodine based platform technologies have been developed. The company’s award-winning Cupertino-based products continue to find their way to market through a series of organic growth initiatives. The license of the Isan System to Clarion Water is progressing and is expected to continue in growth and in financial contribution.
Furthermore, in December of 2015, BioLargo received additional financial support and advisory services of up to C$220,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to continue advancing its AOS Filter.
BioLargo’s AOS Filter is currently the buzz of the academia, government, and water treatment worlds. With applications ranging from food and agriculture to ballast water treatment, along with the recognition of an renowned growth partnership company, BioLargo’s game-changing filter technology demonstrates industry-leading decontamination and disinfection capabilities and is positioned for a scale-up and successful commercialization in the tertiary and advanced wastewater treatment market.
Disclosure: In the purview of Section
17(B) of the Securities Act of 1933 and in the interest of full
disclosure, we call the reader's attention the fact that
Equities.com, Inc. may be compensated by the companies profiled in
the Spotlight Companies section. The purpose of these profiles is to
provide awareness of these companies to investors in the micro,
small-cap and growth equity community and should not in any way come
across as a recommendation to buy, sell or hold these securities.
Equities.com is not a registered broker, broker dealer, investment
advisor, analyst, investment banker or underwriter. All profiles are
based on information that is available to the public. The information
contained herein should not be considered to be all-inclusive and is
not guaranteed by Equities.com to be free from misstatement or
errors. Readers are reminded to do their own due diligence when
researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer